Edison Investment Research - Pharmaceutical & healthcare - ASIT Biotech: On July 11 ASIT biotech raised €12m in commitments in a heavily oversubscribed convertible bond placement. In raising this additional capital, ASIT outlined the primary use of the proceeds which is to fund the Phase III study of its short-course grass pollen allergy immunotherapy (AIT) product gp-ASIT+. An update was provided on its earlier-stage products – house dust mite and peanut allergy AITs. We speculated on the latter in our initiation note and it is now confirmed.
ISIN: BE0974289218
Original Article: ASIT biotech (ASIT) - All go on Phase III